DRUGS

Scope & Guideline

Catalyzing Progress in Pharmacology and Medicine

Introduction

Welcome to the DRUGS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of DRUGS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0012-6667
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1971 to 2024
AbbreviationDRUGS / Drugs
Frequency18 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The journal 'DRUGS' focuses on advancing the understanding of pharmacological agents and their therapeutic applications, particularly in the context of biosimilars, immunotherapy, and innovative drug delivery systems. It aims to bridge the gap between clinical practice and research, providing insights into safety, efficacy, and the economic implications of drug therapies.
  1. Biosimilars and Biologics:
    A core area of focus is the development, safety, and efficacy of biosimilar drugs, including their interchangeability with originator biologics and the economic impact of their adoption in clinical settings.
  2. Immunotherapy Advances:
    The journal emphasizes the latest advancements in immunotherapy, particularly regarding monoclonal antibodies and CAR-T cell therapies, exploring their mechanisms of action and clinical applications across various diseases.
  3. Pharmacokinetics and Drug Safety:
    Research on pharmacokinetics, safety profiles, and immunogenicity of therapeutic agents is a significant scope, providing crucial data for clinicians and regulatory bodies.
  4. Gene Therapy and Novel Therapeutics:
    The journal covers emerging topics in gene therapy and novel therapeutic agents, focusing on their potential to treat genetic disorders and various malignancies.
  5. Real-World Evidence and Economic Evaluations:
    A consistent focus is placed on real-world evidence and economic evaluations of drug therapies, assessing their impact on healthcare systems and patient outcomes.
The journal 'DRUGS' has observed a notable shift towards specific emerging themes in recent years, reflecting the dynamic landscape of pharmacological research and clinical practice.
  1. Biosimilar Research and Policy:
    Increasing attention is being paid to the regulatory, economic, and clinical implications of biosimilars, including studies on their adoption, patient perceptions, and health policy impacts.
  2. Innovations in Immunotherapy:
    There is a growing trend towards researching novel immunotherapeutic approaches, including the use of CAR-T cells and immune checkpoint inhibitors, highlighting their expanding role in cancer treatment.
  3. Gene Editing and RNA-Based Therapies:
    Emerging themes include the application of gene editing technologies like CRISPR and RNA-based therapies, which are being explored for their potential to revolutionize treatment for various genetic disorders.
  4. Real-World Data Utilization:
    The utilization of real-world data to assess treatment outcomes and economic evaluations is trending, as researchers seek to understand the effectiveness of therapies in everyday clinical settings.
  5. Patient-Centric Research:
    There is a notable increase in studies focusing on patient perspectives and experiences with treatments, particularly regarding biosimilars and biologics, reflecting a shift towards more personalized medicine.

Declining or Waning

While the journal continues to explore a wide range of therapeutic areas, certain themes appear to be losing prominence in recent publications. This may reflect evolving research priorities and advancements in drug development.
  1. Traditional Small-Molecule Drugs:
    There seems to be a declining emphasis on traditional small-molecule drugs, as the focus shifts more towards biologics and biosimilars, which are gaining prominence in the treatment landscape.
  2. Conventional Vaccine Development:
    The exploration of conventional vaccine development, particularly for established diseases, has waned, possibly overshadowed by the rapid advancements in mRNA and other novel vaccine platforms.
  3. General Pharmacology Studies:
    General pharmacology studies that do not focus on specific therapeutic agents or diseases are less frequently published, as the journal increasingly prioritizes targeted research with clinical implications.

Similar Journals

Drug Healthcare and Patient Safety

Exploring the intersection of pharmacology and policy.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1365Frequency: 1 issue/year

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

CLINICAL THERAPEUTICS

Empowering clinicians with evidence-based therapeutic advancements.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

International Journal of Pharmacology

Fostering Global Dialogue in Pharmacology and Toxicology
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

CLINICAL DRUG INVESTIGATION

Advancing knowledge in clinical pharmacology.
Publisher: ADIS INT LTDISSN: 1173-2563Frequency: 12 issues/year

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

CURRENT PHARMACEUTICAL DESIGN

Exploring Breakthroughs in Pharmacology and Drug Design
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Fostering excellence in pharmacological sciences and clinical practice.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Drug Discoveries and Therapeutics

Bridging research and practice in drug therapeutics.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Advancing ocular health through innovative research.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Empowering healthcare through cutting-edge pharmacological research.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

International Journal of Pharmaceutics-X

Pioneering research at the forefront of pharmaceutical sciences.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.